Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer

Reporting results of cancer treatment

1981 • 7,916 citations

One-Sample Multiple Testing Procedure for Phase II Clinical Trials

1982 • 987 citations

A Gompertzian model of human breast cancer growth.

1988 • 685 citations

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1995 • 563 citations

Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

1999 • 508 citations

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy

1987 • 501 citations

Docetaxel.

1995 • 404 citations

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

1995 • 389 citations

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1995 • 324 citations

Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results

1995 • 315 citations

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.

1997 • 281 citations

Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic

1996 • 243 citations

Sequential or Alternating Doxorubicin and CMF Regimens in Breast Cancer With More Than Three Positive Nodes

1995 • 234 citations

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

1995 • 220 citations

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.

1996 • 164 citations

A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer

1994 • 139 citations

Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer

1999 • 130 citations

Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy

1999 • 116 citations

Systemic Therapy of Advanced Breast Cancer

1992 • 81 citations

Progress in chemotherapy for metastatic breast cancer.

1992 • 72 citations

Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer

1999 • 46 citations

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study

1999 • 39 citations

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer

2000 • 21 citations

Anthracycline as second line chemotherapy (CT) for metastatic breast cancer (MBC) patients previously treated with taxotere (TXT)

1997 • 4 citations

A phase II randomized study of doxorubicin (A) alternated to docetaxel (T) (ALT) vs sequential administration of 4 cy of t followed by 4 cy of a (seq) as 1st line ct in mbc pts

1999 • 4 citations